Histamine pharmacology and new CNS drug targets. by Tiligada, E. et al.
RESEARCH
Histamine Pharmacology and New CNS Drug Targets
Ekaterini Tiligada,1 Konstantinos Kyriakidis,1 Paul L. Chazot,2 & M. Beatrice Passani3
1Department of Pharmacology, Medical School University of Athens, Athens, Greece
2 Integrative Neuroscience, School of Biological & Biomedical Sciences, University of Durham, Durham, UK
3Dipartimento di Farmacologia Preclinica e Clinica, Universita´ di Firenze, Firenze, Italy
Keywords
Cognitive impairment; Histamine; H3 and H4
receptors; Multiple sclerosis; Neuropathic pain;
Neuroprotection; New drug targets; Sleep-wake
cycle.
Correspondence
Ekaterini Tiligada, Ph.D., Department of
Pharmacology, Medical School University of
Athens, M. Asias 75, GR-11527 Athens, Greece.
Tel: +30 2107462575;
Fax: +30 2107462554;
E-mail: aityliga@med.uoa.gr
doi: 10.1111/j.1755-5949.2010.00212.x
SUMMARY
During the last decade, the identification of a number of novel drug targets led to the de-
velopment of promising new compounds which are currently under evaluation for their
therapeutic prospective in CNS related disorders. Besides the established pleiotropic regula-
tory functions in the periphery, the interest in the potential homeostatic role of histamine
in the brain was revived following the identification of H3 and H4 receptors some years
ago. Complementing classical CNS pharmacology, the development of selective histamine
receptor agonists, antagonists, and inverse agonists provides the lead for the potential ex-
ploitation of the histaminergic system in the treatment of brain pathologies. Although no
CNS disease entity has been associated directly to brain histamine dysfunction until now,
the H3 receptor is recognized as a drug target for neuropathic pain, sleep-wake disorders,
including narcolepsy, and cognitive impairment associated with attention deficit hyperactiv-
ity disorder, schizophrenia, Alzheimer’s, or Parkinson’s disease, while the first H3 receptor
ligands have already entered phase I–III clinical trials. Interestingly, the localization of the
immunomodulatory H4 receptor in the nervous system exposes attractive perspectives for
the therapeutic exploitation of this new drug target in neuroimmunopharmacology. This re-
view focuses on a concise presentation of the current “translational research” approach that
exploits the latest advances in histamine pharmacology for the development of beneficial
drug targets for the treatment of neuronal disorders, such as neuropathic pain, cognitive,
and sleep-wake pathologies. Furthermore, the role of the brain histaminergic system(s) in
neuroprotection and neuroimmunology/inflammation remains a challenging research area
that is currently under consideration.
Introduction
Histamine [2-(4-imidazolyl)-ethylamine] is an endogenous short-
acting biogenic amine synthesized from L-histidine through the
catalytic activity of the rate-limiting enzyme histidine decar-
boxylase (HDC, EC 4.1.1.22) [1]. Following its discovery 100
years ago [2], histamine has been one of the most studied
substances in medicine for a century, possessing a wide spec-
trum of activities, including its function in neurotransmission
(Fig. 1) [3].
Histamine is synthesized in several cell types of peripheral and
central tissues. The classical source of histamine is the pluripotent
heterogeneous mast cell where it is stored in cytosolic granules
and released by exocytosis to exert several actions in response to
various immunological and nonimmunological stimuli [4]. Non-
mast cell histamine is derived from numerous sources, indica-
tive examples being gastric enterochromaffin-like cells [5], var-
ious types of blood cells [6] and neurons [7,8]. The pleiotropic
regulatory character of histamine in cellular events is attributed to
its binding to four distinct subtypes of G-protein-coupled recep-
tors (GPCRs), designated H1, H2, H3, and H4 that are differentially
expressed in various cell types [9]. In humans, the endogenous
ligand shows low affinity for H1 and H2 receptors, whereas its po-
tency on H3 and H4 receptors is considerably higher. H3 and H4
receptors are most closely related to each other and they have a
closer phylogenetic relationship with peptide ligand GPCRs, while
they are remotely related to other biogenic amine receptors, in-
cluding H1 and H2 receptors [10].
It is currently accepted that all four subtypes of histamine re-
ceptors play as yet ill-defined roles in the central nervous system
(CNS) [3]. While data on the contribution of histamine recep-
tors in brain physiology and disease states continue to emerge in
the literature [11], the H3 receptor is a recognized drug target for
neuronal diseases, such as cognitive impairment, schizophrenia,
epilepsy, sleep-wake disorders and neuropathic pain, and the first
H3 receptor ligands have been taken into clinical studies (Table 1)
[cf. 12]. Interestingly, the very recent demonstration of H4 re-
ceptor functional expression in the CNS (Fig. 2) [13] may have
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Figure 1 Schematic representation of central histaminergic components.
In the adult vertebrate brain, histamine (HA) is formed in histaminergic neu-
rons of the tuberomammillary nucleus (TMN) of the posterior hypothalamus
from l-histidine through one-step catalytic action of histidine decarboxylase
(HDC) (1). HA is stored inpresynaptic secretory vesicles (2), and released into
the extracellular space (3) to activate four subtypes of postsynaptic G pro-
tein (G)-coupled receptors (4) designated H1 to H4, thus eliciting a variety of
physiological responses as indicated in the figure. Activation of postsynap-
tic H1 receptors has been associated with enhanced vigilance and attention
and decreased feeding, while stimulation of the postsynaptic H2 receptors
has been linked to enhanced working memory [18]. Binding to postsynaptic
H3 and, possibly, H4 receptors leads to as yet poorly defined actions (?),
which are currently undergoing rigorous investigation. Stimulation of presy-
naptic H3 autoreceptors (5) inhibits (-) HA synthesis (1) and/or release (3),
while HA binding to presynaptic H3 receptors on nonhistaminergic neurons
(6) inhibits the release of a number of neurotransmitters, including acetyl-
choline (ACh), dopamine (DA), noradrenaline (NA), serotonin (5-HT), and
others in a pathway-dependentmanner. HA is inactivated (7) predominantly
by methylation through neuronal histamine N-methyltransferase (HNMT),
without excluding the contribution of diamine oxidase (DAO) as a salvage
pathway to produce imidazole acetic acid, a γ -aminobutyric acid (GABA)A
receptor agonist. Additional sources of brainHAmay include (hypothalamic)
mast cells and other nonneuronal components [cf. 3].
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Table 1 Histamine H3 receptor ligands in clinical evaluation
Disorder Compound Condition Phase Study identifiera
Narcolepsy BF2.649 EDS III NCT01067222
BF2.649 Cataplexy (add on Modafinil) III NCT01067235
GSK-189254 IIc NCT00366080
JNJ-17216498 IIb NCT00424931
PF-03654746 EDS II NCT01006122
ADHD MK-0249 IIb NCT00475735
PF-03654746 IIb NCT00531752
Alzheimer’s disease GSK-239512 (mild to moderate) II NCT01009255
MK-0249 Cognitive function Ic NCT00874939
MK-0249 IIb NCT00420420
PF-03654746 (mild to moderate) I NCT01028911
Schizophrenia BF2.649 Cognitive function II NCT00690274
GSK-239512 Cognitive function II NCT01009060
MK-0249 Cognitive function IIb NCT00506077
Parkinson’s disease BF2.649 EDS IIb NCT00642928
BF2.649 EDS III NCT01036139
Neuropathic Pain GSK-189254 Hyperalgesia Ib NCT00387413
ADHD, attention deficit hyperactivity disorder; EDS, excessive daytime sleepiness; BF2.649, tiprolisant, [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine
hydrochloride] [46,47]; GSK-189254, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride [54].
awww.clinicaltrials.gov.
bCompleted.
cTerminated.
implications for the therapeutic potential of these receptors in cen-
tral disorders, in addition to their topicality as a potential drug tar-
get for inflammatory conditions [14].
The complex brain histamine neurophysiology [3,15,16] and its
receptor ligand pharmacology [12,17,18] have been extensively
reviewed in the recent literature. This contribution highlights the
challenging novel new CNS drug targets introduced by the latest
advances in histamine pharmacology, predominantly pertaining
to the H3 and H4 receptors, and focuses on a concise presentation
of the very recent data supporting the “bench-to-bedside” concept
and future directions for the potential exploitation of the histamin-
ergic system in the treatment of brain pathologies.
Histamine in the Brain
The presence of histamine in the brain was first shown more than
60 years ago [19,20]. Early indirect pharmacological evidence for
the role of histamine in the brain was provided by the sedative
side effects of classic antihistamines used for the treatment of al-
lergies and by the interactions, particularly with the H1-receptor,
of a number of drugs commonly used in neuropsychiatry, in-
cluding typical or atypical antipsychotics and antidepressants [21].
However, research into the significance of histamine in the CNS
has been delayed for many decades, as a possible correlation of
these interactions to the therapeutic actions of neuropsychiatric
medication was overlooked and any histamine-related effects of
these agents were regarded solely as side effects resulting from
their complex pharmacology [22]. More importantly, the well-
established strong association of histamine with peripheral mast
cells and with the pathophysiology of atopic diseases [4] seems to
have deterred neuroscientists from the investigation of this bio-
genic amine.
Despite the structural and functional identification of the mostly
excitatory H1 and H2 receptors in the CNS, the important ac-
tions of histamine in the brain were recognized in the 1980s
[8,23] in parallel with the identification of H3 autoreceptors that
control the activity of histaminergic neurons [7]. Since then,
ongoing related research continues to provide evidence for the
(patho)physiological significance of the histaminergic system in
the CNS and for a better understanding of the actions of therapeu-
tic agents, such as the H4 receptor binding of several neuroactive
drugs, including amitriptyline and clozapine and the recently iden-
tified H1 receptor-mediated orexigenic actions of the antipsychotic
clozapine in the hypothalamus [24].
Histamine does not penetrate the blood–brain barrier; hence its
biosynthesis in the brain is elicited in one step by HDC (Fig. 1) and
is controlled by the availability of L-histidine [cf. 3]. Unlike other
biogenic amines, histamine is not a direct inhibitor of its biosyn-
thetic enzyme, S-α-fluoromethylhistidine being a selective and po-
tent HDC “suicide” inhibitor [25]. In the adult vertebrate brain,
histamine is formed in histaminergic neurons of the tuberomam-
millary (TM) nucleus of the posterior hypothalamus that project
to all major areas of the brain, whereas data on the afferent con-
nections are relatively limited [3,15]. Neuronal histamine is stored
in cell somata and in axon varicosities, while its synthesis and re-
lease are controlled mainly through H3 autoreceptors on the so-
mata, dendrites and axons (Fig. 1). Histamine acts postsynaptically
via H1, H2, H3, and H4 receptors, and it is inactivated by methy-
lation through neuronal histamine N-methyltransferase (HNMT,
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Figure 2 Histamine (A) H3 and (B) H4 receptors expressed in the mouse
spinal dorsal horn. Paraformaldehyde (4%)-fixed adult murine spinal cords
were dehydrated using sucrose infiltration, with 10% sucrose, then 20% su-
crose made up with phosphate buffered saline, and snap-frozen in iso-
pentane −70◦C for 1 minute and stored at −80◦C. Cryoslices (20 μm thick-
ness) were probed with either (A) anti-H3 and (B) anti-mH4 receptor anti-
bodies essentially as described previously [35,38]. Arrows and arrowheads
indicate H3 and H4 receptor expression, respectively. Bar = 200 μm.
EC 2.1.1.8), without excluding the contribution of diamine oxi-
dase (DAO, EC 1.4.3.6), which converts histamine into imidazole
acetic acid, a γ -aminobutyric acid (GABA)A receptor agonist [cf.
Ref. 3].
So far, no direct association between a neuronal disease and
brain histamine dysfunction has been identified. In a mutual inter-
action network with other transmitter systems, brain histamine is
implicated in basic homeostatic and higher brain functions, includ-
ing sleep-wake regulation, circadian and feeding rhythms, body
temperature, locomotor activity, learning, and memory [3]. Rela-
tively recently, attention has been drawn to the role of histamine
in autoimmune diseases and neuroinflammation [26,27], while
H4 receptors, which are primarily, but not exclusively, distributed
in immune cells [10] may be involved in a number of elaborate
homeostatic and integrative interactions between the immune and
nervous systems.
Besides neuronal histamine, mast cells, which are fundamen-
tal in peripheral immune and atopic responses [4], seem to be an
additional source of brain histamine (Fig. 1). Mast cells appear
to act as gatekeepers at interfaces between the CNS and the en-
docrine and immune systems [28–31], as they can migrate into
the brain, particularly during development [32] and under some
pathological conditions [33].
Histamine H3 Receptors
Studies on histamine function in the CNS have been focused
largely on the effects mediated via H3 receptor signaling [7].
H3 receptors are located on TM neurons and are mainly ex-
pressed in cerebral cortex, hippocampus, amygdala, nucleus ac-
cumbens, globus pallidus, striatum, thalamus, and hypothalamus
[34,35]. The human H3 receptor gene is located on chromosome
20q13.33 and encodes a 70 kDa 445 amino acid peptide belong-
ing to the GPCR family [36], showing very low sequence simi-
larity with other GPCRs and only 22% and 20% similarity with
H1 and H2 receptors, respectively [17]. Downstream signalling is
mediated through Gi/o proteins and consequently the negative
coupling of the receptor to adenylyl cyclase downregulates cAMP-
dependent activation of protein kinase A and cAMP-response-
element-binding protein-induced gene transcription. Additional
interactions with other effector signalling cascades include the ac-
tivation of phospholipase A2, as well as the mitogen-activated pro-
tein kinase and phosphatidylinositol 3-kinase pathways (PI3K),
which activate extracellular signal-regulated kinases and Akt and
subsequently inhibit the action of glycogen synthase kinase 3β
(GSK3β), thus playing important roles in neuronal apoptosis, ax-
onal and synaptic plasticity and being associated with Alzheimer’s
disease, ischemia or Parkinson’s disease, diabetes, and/or insulin
resistance [cf. 3,17].
The H3 autoreceptor function in the negative feedback con-
trol of histamine synthesis and release from histaminergic neu-
rons [7], as well as the cross-talk of the H3 heteroreceptor with
other neurotransmitters, including acetylcholine, dopamine, sero-
tonin, and noradrenaline (Fig. 1) [18], play a major role in brain
physiology [3], illustrated by the high H3 receptor constitutive
or spontaneous activity in vivo [37]. However, H3 receptors show
species differences and pronounced molecular and functional het-
erogeneity achieved through differential splicing. The large num-
ber of isoforms exhibit differential distribution and pharmacologi-
cal patterns that have complicated the extrapolation of preclinical
data into the clinic [17]. The challenge is even greater than ini-
tially expected because of the complexity of the central histamin-
ergic system, the diversity of actions, the overlapping structure-
affinity/efficacy relationships and pharmacology of H3 and H4
receptor-targeting compounds and the differential opposing effects
of some H3 ligands in a number of experimental models [16]. Yet,
the usefulness of H3 receptor ligands in the treatment of patho-
physiological states evoked by an imbalance of histaminergic inter-
actions are currently under intense investigation, while a number
of H3 receptor ligands are on their way to the clinic (Table 1).
Despite the evidence on the contribution of postsynaptic H1
and/or H2 receptors in histamine-mediated transmission and in
cellular mechanisms involved in arousal and cognitive functions
[16], translational research has been directed towards the ther-
apeutic potential of antagonists and inverse agonists targeting
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selectively the H3 receptor, based on a relatively complex ra-
tionale, without any proof of concept for an H3 receptor
(patho)physiological function reported so far [12].
Histamine H4 Receptors
Following identification of the H4 receptor some 10 years ago by
several groups simultaneously, accumulating evidence points to
its regulatory role in immune and inflammatory responses [14].
Contrary to the H3 receptor predominant neuronal localization,
H4 receptors are primarily, but not exclusively, distributed in im-
mune cells, including mast cells, eosinophils, dendritic, and T cells
in peripheral tissues such as spleen, thymus, colon, blood and bone
marrow, thereby eliciting chemotactic actions [cf. 14].
Importantly, however, the recently reported functional expres-
sion of H4 receptors on human and rodent neurons (Fig. 2)
highlights their implication in neuronal functions [13,38–41]. H4
receptor expression was detected in distinct deep laminae in the
human cortex [13], hippocampus, thalamus, amygdala, and spinal
cord [39]. Expression of H4 receptors has been reported in mouse
thalamus, hippocampal CA4 stratum lucidum, and layer IV of the
cerebral cortex, where they appear to induce hyperpolarization
and promotion of outwardly rectifying currents [13], as well as in
motor neuron subpopulations of the murine spinal cord [38]. In
the rat, H4 mRNA has been detected in cortex, cerebellum, brain-
stem, amygdala, thalamus, striatum, dorsal root ganglia, and spinal
cord, while very low levels were detected in the hypothalamus and
no H4 mRNA signal in the hippocampus [39]. Recently, the H4 re-
ceptor antagonist, JNJ-7777120, subjected intraperitoneally (i.p.)
in rats reduced exploratory behavior in a dose-dependent manner
[41], which may indicate a role of the H4 receptor in motor func-
tion and/or anxiety responses, consistent with its anatomical pro-
file. This requires further investigation in appropriately validated
behavioral tests which discriminate these activities.
The human H4 receptor gene is located in a single copy on chro-
mosome 18q11.2 and encodes a 390 amino acid peptide belong-
ing to the GPCR family, sharing ∼35% amino acid identity with
the H3 receptor, with ∼58% homology in its transmembrane re-
gions, and only ∼19% sequence similarity to the H1 and H2 re-
ceptors. Similarly to the H3 receptor, the H4 receptor is coupled
to pertussis toxin-sensitive Gi/o proteins consequently inhibiting
forskolin-induced cAMP and eventually modulating the transcrip-
tion of genes regulated by cAMP-responsive elements [cf. 10]. At
present only two nonsignalling H4 receptor isoforms have been
identified, which may act as regulatory elements [42].
The similarities between H3 and H4 receptors and the over-
lap in their pharmacological profiles along with the high struc-
tural and pharmacological species differences displayed by the re-
ceptors and their ligands, particularly in terms of their potency,
efficacy and functional selectivity [10], have resulted in frequent
misinterpretations of preclinical data. Efforts are currently focused
on the development of selective compounds that would provide
effective pharmacological tools to assess the central and peripheral
physiological role and the therapeutic potential of the H4 recep-
tor [12]. The high patent filing activity in this field resulted in the
advancement of the H4 receptor antagonist UR-63325 to Phase I
clinical trials for respiratory diseases, while further H4 receptor-
targeting agents developed by many pharmaceutical companies
and academic departments show promise for potential entry into
clinical studies.
Histamine Receptors as New CNS Drug
Targets
Sleep-Wake Disorders
The TM nucleus and the adjacent posterior hypothalamus are cru-
cial for wakefulness. TM neurons, tuned via GABAA receptors ac-
tivated by the GABAergic input from the ventrolateral preoptic
area, project to various brain regions that control the sleep-wake
cycle, such as the cortex, thalamus, preoptic and anterior hypotha-
lamus, brainstem and forebrain, while histamine release in the
prefrontal cortex is strictly correlated to waking [3,16]. The con-
certed action of this biogenic amine on H1, H2 and H3 receptors
exerts a tonic wake-selective activity pattern in the brain, which
seems to be responsible for the qualitative cognitive aspects and
cortical electroencephalogram activation in wakefulness, whereas
orexin elicits a distinct, yet synergistic control with histamine by
being involved mainly in the behavioral aspects of wakefulness
[16,43]. H1 receptor agonists and/or H3 antagonists are promising
targets for the treatment of hypersomnia, while H1 receptor antag-
onists and/or H3 agonists could be useful in controlling insomnia
[44]. Despite the sedative effect of most clinically used antihis-
tamines, some of which are marketed as sleep aids due to their
daytime drowsiness side effects, they are of limited use in control-
ling insomnia as they have long half-lives, peripheral side effects
and show inconsistent sedative patterns [45].
Selective ligands targeting the H3 autoreceptor have been
shown to be modulators of sleep phenomena and associated
pathologies, such as hypersomnia, daytime somnolence and the
rare but unsatisfactorily treated sleep disorder, narcolepsy [12,45].
Among the H3 receptor antagonists that have been used in related
preclinical studies, JNJ-17216498 and GSK-189254 advanced to
the phase II clinical trials for the treatment of narcolepsy [18].
The cyclobutyl amide PF-03654746 is under clinical evaluation
for its efficacy in improving alertness and awakeness in patients
with narcolepsy-associated excessive daytime sleepiness (EDS)
(Table 1). Furthermore, the H3 receptor nonimidazole inverse ago-
nist BF2.649 (tiprolisant) significantly reduced EDS in narcoleptic
patients and currently running clinical trials are showing that it
is a very promising alerting drug in Parkinson’s Disease (Table 1)
[46,47]. Tiprolisant passed clinical phase II studies and approved
orphan drug status by the European Medicines Agency (EMEA)
for the therapeutic treatment of narcolepsy.
Cognitive Disorders
Impaired cognitive functions accompany neuropsychiatric and
neurodegenerative diseases such as Alzheimer’s disease, atten-
tion deficit hyperactivity disorder (ADHD), or schizophrenia,
where most treatment strategies have focused on a single neu-
rotransmitter system, even though disruption of multiple neu-
rotransmitter systems is apparently involved. Histamine acting
on postsynaptic H1 and H2 receptors functions as an excitatory
neurotransmitter and plays a key role in attention and vigi-
lance. Blockade of presynaptic H3 autoreceptors would therefore
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indirectly enhance histamine-mediated attention in cognitive dis-
orders such as ADHD and Alzheimer’s disease [48]. Besides con-
trolling histamine release through the presynaptic H3 autore-
ceptors, H3 ligands may control the release of other transmitter
systems (Fig. 1) involved in cognitive processes [16,18].
An ongoing phase II clinical trial aims to evaluate the cogni-
tive enhancing effects of the H3 receptor antagonist GSK-239512
in patients with mild to moderate Alzheimer’s disease. In this re-
gard, [3H]GSK-189254 binding in hippocampal and cortical sec-
tions from patients with advanced Alzheimer’s disease is an im-
portant observation, suggesting that H3 expression is still prevalent
even in severe late stages of the disease [48]. Other compounds,
such as MK-0249 and PF-03654746 await evaluation for their ef-
fectiveness in the treatment of ADHD (Table 1).
Furthermore, tiprolisant having completed phase II trials and
showing efficacy in patients suffering from antipsychotic-induced
weight gain, is currently under evaluation for its cognitive enhanc-
ing effects in patients with schizophrenia and schizoaffective dis-
order (Table 1). In addition to the histaminergic and dopaminergic
hyperactivity observed in schizophrenia, postsynaptic H3 recep-
tors show additive activation with striatal dopamine D2 receptors
in generating some of the disease symptoms, thus supporting the
interest of H3 receptor inverse agonists as antipsychotics, either
alone or as adjunctive treatment with classical neuroleptics [49].
A very interesting feature of H3 receptor antagonists/inverse ag-
onists is that several of them produce cognitive enhancing effects
at much lower doses than those required to elicit a robust wake
enhancement [50,51]. Ideally, different compounds could be used
for the treatment of sleep-wake cycle disorders or cognitive im-
pairments.
Neuropathic Pain
Neuropathic pain is relatively common and largely resistant to
treatment mainly because of the poorly understood underlying
mechanisms, which include ectopic excitability of sensory neu-
rones, sensitization of neurones in the dorsal horn of the spinal
cord and, more recently, inflammatory and immune pathways
[52]. Histamine as well as mast cells have been strongly implicated
in the pathophysiology of neuropathic pain, while both H3 [53]
and H4 [41] receptors seem to contribute to the underlying mech-
anisms. The existing data have been somewhat conflicting, mostly
because of the use of experimental models with questionable rele-
vance to the clinical situation and of the species-differences and
complex pharmacology of the compounds used, such as thiop-
eramide, which it is now known to possess both H3 and H4 re-
ceptor activity [12,52].
Novel selective H3 receptor antagonists/inverse agonists, such as
GSK-189254 and GSK-334429, are effective in surgically induced
and virally induced rat models of neuropathic pain [54]. Histamine
produces itch which might be converted into pain in neuropathic
hyperalgesia [55]. Regarding H4 receptors, the antihyperalgesic
and antinociceptive effects of the H4 receptor antagonist JNJ-
7777120 have been suggested to be secondary to its antiinflam-
matory action [41]. JNJ-7777120 exhibited robust antinociceptive
activity in persistent inflammatory (complete Freund’s adjuvant-
induced) pain, effectively reversed monoiodoacetate-induced os-
teoarthritic joint pain and produced dose-dependent antiallodynic
effects in the spinal nerve ligation and sciatic nerve constriction
injury models of chronic neuropathic pain, as well as in a skin-
incision model of acute postoperative pain, with ED50 values rang-
ing from 29–88 mg/kg i.p. [41]. Although investigations utiliz-
ing H3 and/or H4 receptor ligands have to be evaluated carefully,
H3 receptors in the human dorsal root ganglia and dorsal horn
of the spinal cord seem to play a role in linking peripheral and
central sensitization pathways [54]. Moreover, the recent demon-
stration of the functional expression of H4 receptors in the brain
and the strong expression in human and rodent spinal cord (Fig.
2) [13,38,39], together with the involvement of inflammatory and
immune components in neuropathic pain is directing current re-
search to the investigation of a wider contribution of the H4 recep-
tors in itch and pain [56].
The overall outcome of preclinical investigations led to phase
I clinical trials of the highly potent histamine H3 receptor antag-
onist GSK-189254 (Table 1), which demonstrated efficacy in the
reduction of mechanical hyperalgesia and allodynia in the chronic
constriction injury preclinical model of neuropathic pain, possibly
through enhanced release of monoamines in the CNS [54].
Future Directions
Histamine and Neuroprotection
Antagonists/inverse agonists of the H3 receptor have raised much
interest in the scientific community for their potential clinical use
[12], yet there are potential therapeutic applications for H3 recep-
tor agonists as well, that deserve consideration.
In addition to the modulation of the wake promoting effect
of histamine, novel effects of H3 receptor activation have ap-
peared in the recent literature, including an antinociceptive role
for spinal H3 receptor activation [57]. Recently, several studies
have hinted at a role of the histaminergic system and H3 receptor
in neuroprotection. The hypothesis came from Panula and collab-
orators who provided clear indications of the plasticity of brain
histaminergic system following injury or neurotoxic insults. H3
receptor mRNA was shown to be upregulated in the rat caudate
and putamen following induction of transient global cerebral is-
chemia [58], or in the rat cortex following kainic acid-induced
seizures [59], although with different time courses and recov-
ery. More recently the same group elegantly demonstrated that
histamine protects hippocampal neurons from damage induced
by kainic acid in organotypic cocultures of hypothalamic and
hippocampal tissue [60], where histamine released from hypotha-
lamic neurons affords the neuroprotective effect of hippocam-
pal neurons presumably by activating postsynaptic H1 receptors.
On the other hand, blockade of presumably presynaptic autoin-
hibitory H3 receptors ameliorates the protective effect of histamin-
ergic neurons [60].
In cultured murine cortical neurons, though, where no his-
taminergic neurons are present, and H3 receptors are abundantly
expressed, H3 receptor stimulation activates antiapoptotic sig-
naling cascades, such as the PI3K/Akt/GSK-3β pathway [61].
The Akt pathway has been implicated in regulating several im-
portant cellular processes, including cell plasticity and survival,
proliferation and metabolism. Indeed, in cultured cortical cells,
H3 receptor agonists increase the expression of the inhibitor of
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apoptosis Bcl-2 and decrease the expression of proapoptotic ele-
ments such as caspase-3, following neurotoxic insults [61]. Hence,
stimulation of H3 receptors protects cortical neurons from N-
methyl-D-aspartate-induced neurotoxic insults and this obser-
vation may have relevance in the prevention of, for instance,
ischemic neuronal damage or neurodegenerative diseases. As a
matter of fact, evidence points to a key role for GSK-3β in pro-
moting neurodegeneration [62] and it is involved in a cascade
of events, such as hyperphosphorylation of tau protein, increased
production of β-amyloid, local cerebral inflammatory responses
that may culminate in Alzheimer’s disease [63]. In this regard,
binding studies showed that the expression of H3 receptors is
spared in the brain of Alzheimer’s and Lewy Body Dementia pa-
tients [48, Lethbridge, Medhurst, & Chazot, unpublished]. To fully
understand the impact of H3 receptor-induced activation of anti-
apoptotic pathways in the CNS, in vivo experiments are necessary,
the more so as H3 receptor antagonists are now viewed as potential
therapeutics for schizophrenia and Alzheimer’s disease (Table 1).
Multiple Sclerosis
Multiple sclerosis (MS) is the most common nontraumatic cause of
neurological disability among young adults inWestern Europe and
North America and existing therapies are partly effective in halt-
ing ongoing inflammatory tissue damage and clinical progression.
MS pathogenesis is complex and probably heterogeneous among
patients, suggesting that combination therapy strategies that tar-
get a range of disease mechanisms might be more effective than
medications used as monotherapy [64].
Increasing evidence indicates that histamine is also involved
in the pathophysiology of MS and its most widely used ani-
mal model, experimental autoimmune encephalomyelitis (EAE)
[27,65]. The interest in histaminergic compounds for the treat-
ment of MS stems mostly from preclinical studies although in a
small pilot study as well, a cohort of MS patients treated with
the H1 receptor antagonist hydroxyzine showed signs of neuro-
logical amelioration [66]. Recent evidence indicates a role for H1
receptors in autoimmune demyelination and extensive involve-
ment of elements of the immune response associated with allergy
in EAE [67]. H2 receptors also seem to regulate in part encephali-
togenic T cell responses and EAE susceptibility, as mice lacking H2
receptors present less severe acute, early-phase of the disease [68].
Moreover, H3 receptor knock-out mice developed a more severe
form of EAE than their wild type littermates, an effect that the au-
thors attributed to altered blood–brain barrier permeability [68].
Considering the immunoregulatory role of the H4 receptor in in-
flammatory responses and the compelling evidence associating H4
receptors with atopic and autoimmune disorders [14,56], it is in-
triguing to speculate an H4 receptor role in EAE and the possible
attenuation of the immune response and amelioration of the neu-
rological signs following blockade of the H4 receptor, a hypothesis
that is currently under investigation.
Concluding Remarks
The identification of the histamine H3 and H4 receptors is piv-
otal in refining our understanding of the pharmacology and the
therapeutic potential of this biogenic amine. Classically estab-
lished as a “peripherally” important mediator of inflammation,
histamine is now accepted to play a role in neurotransmission
(Fig. 1) and to provide new CNS drug targets, similarly to the
other biogenic amine systems exploited by neuropharmacology,
including noradrenalin, dopamine and serotonin, which are ma-
jor targets for medication commonly used in neuropsychiatry. His-
tamine exerts its central effects through H1, H2, and H3 receptors.
The latter, whether presynaptic autoreceptors that inhibit the syn-
thesis and release of histamine in the histaminergic neurones or
postsynaptic heteroreceptors, are predominately distributed in the
CNS and seem to be a suitable target for CNS drug development.
Furthermore, the recent intriguing observation of the functional
expression in enteric and central neurons of the predominantly
peripheral H4 receptor (Fig. 2), which is undergoing rigorous char-
acterization at present, adds further complexity to the role of his-
tamine in the CNS. Thus, a potential interaction of the histamine
receptors in the overall brain (patho)physiolology cannot be ex-
cluded at present.
Although important questions regarding the (patho)physiology
of the central histaminergic system remain to be answered, H3
receptors have gained widespread attention by various academic
and industrial laboratories for the development of ligands cur-
rently undergoing extensive preclinical pharmacological profiling
for clinical candidate selection in a plethora of experimental mod-
els of human diseases. A number of antagonists and inverse ag-
onists have advanced into clinical assessment (Table 1) for their
safety and effectiveness in disorders of the sleep-wake cycle such
as narcolepsy, in neuropathic pain and as cognition enhancers in
ADHD, schizophrenia, Alzheimer’s, and Parkinson’s disease, the
results of these clinical trials being eagerly awaited. Moreover, the
increasing evidence for a role of the histaminergic system in neu-
roprotection and in the pathophysiology of MS has started to mo-
tivate vigorous related investigations in order to progress our un-
derstanding of the properties of histamine and its receptors, and to
meet the challenge of identifying potential new drug targets in the
neuropsychiatric and neuroimmunological arenas.
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